A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and the postoperative survival of early-stage NSCLC patients remains unsatisfactory. Over the last several decades, mutant genes, immunological checkpoints, and blood-based biomarkers have been dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Weibo, Tang, Quanying, Zeng, Jingtong, Jin, Xin, Zu, Lingling, Xu, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526902/
https://www.ncbi.nlm.nih.gov/pubmed/37760531
http://dx.doi.org/10.3390/cancers15184561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526902/
https://www.ncbi.nlm.nih.gov/pubmed/37760531
http://dx.doi.org/10.3390/cancers15184561

Ejemplares similares